title: Linaclotide for treatment of irritable bowel syndrome--the view of European regulators.
authors.affiliation: European Medicines Agency, London, United Kingdom. Electronic address: michael.berntgen@ema.europa.eu.
authors.forename: Michael
authors.initials: M
authors.lastname: Berntgen
authors.forename: Harald
authors.initials: H
authors.lastname: Enzmann
authors.forename: Elmer
authors.initials: E
authors.lastname: Schabel
authors.forename: Concepcion
authors.initials: C
authors.lastname: Prieto Yerro
authors.forename: Antonio
authors.initials: A
authors.lastname: Gómez-Outes
authors.forename: Tomas
authors.initials: T
authors.lastname: Salmonson
authors.forename: Joachim
authors.initials: J
authors.lastname: Musaus
mesh_terms: D003248:Constipation / Q000188:drug therapy* / Q000209:etiology; D017277:Drug Approval; D005060:Europe; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000150:complications / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D000074261:Receptors, Enterotoxin; D050705:Receptors, Guanylate Cyclase-Coupled / Q000819:agonists; D018000:Receptors, Peptide / Q000819:agonists; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D010455:Peptides; D018000:Receptors, Peptide; D000074261:Receptors, Enterotoxin; D050705:Receptors, Guanylate Cyclase-Coupled; C523483:linaclotide